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Non-alcoholic fatty liver disease (NAFLD), and the progressive stage non-alcoholic
steatohepatitis (NASH), is the predominant cause of chronic liver disease globally. As
part of the complex pathogenesis, natural killer (NK) cells have been implicated in the
development of liver inflammation in experimental murine models of NASH. However,
there is a lack of knowledge on how NK cells are affected in humans with this disease.
Here, we explored the presence of disease-specific changes within circulating and
tissue-resident NK cell populations, as well as within other major immune cell subsets, in
patients with liver biopsy-confirmed NAFLD. Using 18-color-flow cytometry, substantial
changes were observed in certain myeloid populations in patients as compared to
controls. NK cell numbers, on the other hand, were not altered. Furthermore, only minor
differences in expression of activating and inhibitory NK cell receptors were noted, with
the exception of an increased expression of NKG2D on NK cells from patients with NASH.
NK cell differentiation remained constant, and NK cells from these patients retain their
ability to respond adequately upon stimulation. Instead, considerable alterations were
observed between liver, adipose tissue, and peripheral blood NK cells, independently
of disease status. Taken together, these results increase our understanding of the
importance of the local microenvironment in shaping the NK cell compartment and stress
the need for further studies exploring how NASH affects intrahepatic NK cells in humans.
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INTRODUCTION
NK cells are an important part of innate immunity where they participate in the defense against
viral infections and in tumor surveillance (1) Upon activation, NK cells perform cytotoxicity by the
release of cytolytic granules. They can also contribute to a pro-inflammatory environment through
the production of cytokines and chemokines such as interferon-γ (IFN-γ) and tumor necrosis
factor (TNF) (1). As part of the innate immune system, NK cells were believed to retain a static
phenotype during their life span with little evidence of differentiation except for transition from
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CD56bright to CD56dim NK cells (2). However, this view has
been revised in the last decade and it is now clear that NK cells
gradually undergo directed differentiation even after they have
reached the CD56dim stage (2). In addition to their presence
in the circulation, NK cells are found in numerous peripheral
tissues and are especially enriched in the liver and uterus where
they comprise up to 30 and 45%, respectively, of all lymphocytes
(3, 4). However, compared to circulating NK cells, less is known
regarding NK cells residing in tissues. In relation to the liver,
studies have in recent years shown the importance of NK cells
in the pathogenesis and clearance of chronic viral hepatitis
infections in humans (5). However, the role of NK cells in many
other liver diseases remains elusive.
Non-alcoholic fatty liver disease (NAFLD) is the most
common chronic liver disease worldwide. A sub-group of
NAFLD patients develop chronic inflammation in the liver,
which over time can lead to liver fibrosis. This stage of the
disease is known as non-alcoholic steatohepatitis (NASH) (6)
and these patients are at risk of developing liver cirrhosis,
liver failure, and hepatocellular carcinoma (HCC) (7). The
increased rates of obesity in many countries has contributed
to the drastic global increase in NAFLD prevalence in recent
years (8). Thus, NAFLD complications, such as NASH, liver
cirrhosis, and HCC, are posing a significant challenge to health
care systems worldwide (6). Several theories exist as to why
liver inflammation develops in patients with NAFLD. In more
detail, disease development is believed to be influenced by an
interplay between genetic and environmental factors, ranging
from disturbances in lipid storage and metabolism, changes in
dietary patterns and microbiota, to perturbed immune activation
(6). However, the exact mechanisms as to why some patients
progress in their disease whilst others do not still remain elusive.
Interestingly, murine models have revealed the importance
of innate immunity, and in particular NK cells, during NASH-
development (9). Many NK cell ligands are up-regulated in
the liver of mice with NASH and this is followed by influx of
activated cytotoxic NK cells (10, 11). Furthermore, NK cells can,
via Tumor necrosis factor (TNF)–related apoptosis-inducing
ligand (TRAIL) production, promote a pro-inflammatory state
in the steatotic liver and by this mechanism contribute to
progression toward steatohepatitis (10). In addition, NK cell
activation in response to IL-15 promotes NASH-development
in mice (12) and NK cells are also thought to play an
important role in regulating fibrosis development in NASH
(13, 14). In addition, obesity itself can also alter NK cell
phenotype, metabolism, and function (15–18). Indeed, several
recent studies in mice have suggested NK cells to be important
Abbreviations: ALT, alanine transferase; AST, aspartate transferase; BMI, body
mass index; HCC, hepatocellular carcinoma; HOMA-IR, homeostatic model
assessment; HSC, hepatic stellate cell; IFN-γ, interferon-gamma; IL, interleukin;
ILC1, innate lymphoid cell group 1; KIR, killer cell immunoglobulin-like
receptor; MAIT, mucosa-associated T; mDC, myeloid dendritic cell; NAFL, non-
alcoholic fatty liver; NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic
steatohepatitis; NAS, NAFLD activity score; NK, natural killer; PBMC, peripheral
blood mononuclear cell; pDC, plasmacytoid dendritic cell; SDI, Simpson diversity
index; SNE, stochastic neighbor embedding; TRAIL, TNF-related apoptosis-
inducing ligand; TNF, tumor-necrosis factor.
for development of insulin resistance (19–21). However, there
is a lack of knowledge on how NK cells are affected in
humans with NASH, both with respect to circulating NK cells
as well as to NK cells residing in metabolically active tissues
such as liver and adipose tissue. To address this, we here
performed an in-depth phenotypic and functional analysis of
circulating NK cells in NAFLD patients as well as explored




Several clinical cohorts were included in the current study.
All studies were approved by the regional ethics committee
in Stockholm (Dnr’s: 2010/678-31/3, 2006/971-31/1, 2006/229-
31/3, and 2014/979-31/1) and oral and written informed consent
was obtained from all participants. First, peripheral blood
samples were obtained from 26 patients with liver biopsy-
confirmed NAFLD from the out-patient clinic at the Upper GI
Tract Department, Karolinska University Hospital, Stockholm,
Sweden. SeeTable 1 for detailed patient characteristics. Secondly,
as controls, peripheral blood from 15 healthy blood donors
was collected from the blood bank at the Karolinska University
Hospital, Stockholm, Sweden. Inclusion criteria in controls
were normal body-mass index (BMI), normal liver enzymes
[alanine aminotransferase (ALT) and aspartate aminotransferase
(AST)], and no history of type 2 diabetes. Thirdly, in order
to assess tissue resident NK cells, peripheral blood as well
as liver and adipose tissue biopsies were collected from 26
patients undergoing laparoscopic gastric bypass surgery for
morbid obesity at Danderyd and Ersta Hospitals in Stockholm.
All patients had a BMI above 35 and had no previous
history of liver disease. Included patients were not prescribed
any low-calorie pre-surgery diet since this would influence
degree of liver steatosis and possibly liver inflammation. A
fraction of obtained liver biopsies was used for clinical scoring
of liver histology according to the NAFLD activity score
(NAS) and fibrosis stage. Based on the severity of the liver
histology, patients were divided into three groups; patients with
normal liver histology, patients with liver steatosis only (non-
alcoholic fatty liver, NAFL), and patients with liver inflammation
(NASH). See Table 2 for more detailed characteristics on this
patient cohort.
Isolation of PBMC From Blood Samples
Peripheral blood mononuclear cells (PBMC) were isolated
from blood samples using density gradient centrifugation.
Briefly, whole blood was diluted with phosphate buffered saline
(PBS; Invitrogen, USA), carefully layered on top of Ficoll-
Hypaque (GE Healthcare, UK), and centrifuged. The leukocyte
layer was extracted, carefully washed, and cryopreserved in
freezing medium [90% heat-inactivated fetal bovine serum
(FBS; Sigma-Alderich, USA) and 10% dimethyl sulfoxide
(DMSO; Life Technologies)] until flow cytometry experiments
were performed.
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Subjects 15 11 15
Age, mean (years) 54 56 58
Male, n 10 (67%) 8 (73%) 9 (60%)
Female, n 5 (33%) 3 (27%) 6 (40%)
BMIc mean (kg/m2 ) 24 35 31
ALTd, mean (µkat/L) NA 0.51 0.75
NAFLD Activity Score, median (range) NA 3 (1–4) 5 (5–7)
Steatosis (0–3), median (range) NA 1 (1–2) 2 (1–3)
Lobular inflammation (0–3), median (range) NA 1 (1–3) 2 (1–3)
Hepatocyte ballooning (0–2), median (range) NA 0 (0–1) 2 (1–2)





eFibrosis score according to Kleiner et al. (22).
NA, not applicable.
TABLE 2 | Bariatric surgery cohort characteristics.
Non-NAFLD NAFLa NASHb
Subjects 8 10 5
Age (year), mean 43 45 43
Male 1 (12.5%) 3 (30%) 0 (0%)
Female 7 (87.5%) 7 (70%) 5 (100%)
BMIc, mean (kg/m2) 37 37 37
ALTd (µkat/L), mean 0.37 0.51 0.75
P-Insulin (IUe), mean 14.3 19.8 36.0
P-Glucose (mmol/L), mean 5.6 6.4 6.5
HOMA-IRf, mean 3.6 5.7 10.5
NAFLD Activity Score, median (range) 0 (0) 3.5 (1–4) 5 (5)
Steatosis (0–3), median (range) 0 (0) 1 (1–3) 2 (1–2)
Lobular inflammation (0–3), median (range) NA 1 (0–2) 2 (1–2)
Hepatocyte ballooning (0–2), median (range) NA 1 (0–2) 1 (1–2)






fHomeostatic model assessment—insulin resistance.
gFibrosis score according to Kleiner et al. (22).
Isolation of Immune Cells From Liver and
Adipose Tissue
The core liver biopsies were collected during surgery directly into
complete cell medium [Hyclone RPMI (Invitrogen), 10% FBS,
and 1mM L-glutamine (Invitrogen)] and kept on ice until same-
day processing. Tissue pieces were mechanically dissociated,
followed by enzymatic digestion in collagenase II for 30min
at 37◦C, and filtered through a 100µm filter, before flow
cytometry staining.
Antibody Staining Protocol
Cryopreserved PBMC were thawed in a 37◦C water bath,
immediately transferred to cell medium, washed, and
resuspended in complete cell medium. Three million PBMC
were stained in each test. Flow cytometry primary and secondary
stainings were performed in flow buffer (PBS with 2mM EDTA
and 2% FBS) for 20min in the dark at room temperature.
After staining, cells were fixed for 15min in the dark at
room temperature using the Fix/Perm solution (eBioscience,
USA). Finally, Fix/Perm solution was washed away, cells were
resuspended in flow buffer, and kept at 4◦C in the dark until they
were acquired on the flow cytometer. For intracellular stainings,
cells were permeabilized in Fix/Perm solution for 45min and
then stained for 30min in permeabilization buffer (eBioscience,
USA), diluted 1:10 with MQ water, before being washed and
analyzed. All samples were run on an 18-color LSRFortessa
(BD Biosciences, USA) equipped with 355, 405, 488, 561, and
639 nm lasers.
Functional Experiments
NK cell degranulation and cytokine production were assessed
by co-culture experiments with target cells. PBMCs were pre-
stimulated overnight with IL-12 (10 ng/ml, Peprotech) and IL-18
(100 ng/mL, Medical & Biological Laboratories) and then K562
cells were added at a 1:10 ratio. One hour after addition of
target cells, Golgi plug (Brefeldin A, BD Biosciences) and Golgi
stop (Monesin, BD Biosciences) were added and the assay was
continued for an additional 5 h. NK cells were then stained for
analysis using flow cytometry.
Microscopy
Liver biopsy specimens obtained fromNAFL/NASH patients and
patients undergoing gastric bypass surgery were stained with
hematoxylin and eosin and graded in a blinded fashion by an
experienced hepatologist according to the NAFLD activity score
(NAS) (23). In addition, liver biopsies were stained with Sirius
red to evaluate liver fibrosis and scored according to Kleiner on a
0–4 scale (23).
Flow Cytometry Analysis
To avoid bias from intra-experimental variability that could affect
the flow cytometry analysis, samples from both healthy donors
and patients were analyzed in each experiment. Acquired data
was compensated using a compensation matrix generated based
on antibody-stained control beads and analyzed using FlowJo
Version 9.6.4 (Treestar, USA). Apart from conventional flow
cytometry analysis, Barnes-Hut stochastic neighbor embedding
(SNE) analysis, using an in-house built script (24) in R (The
R Foundation for Statistical Computing), was performed in
order to visualize potential differences not present in two-
dimensional space. For SNE-analysis, 1,000 CD56dim NK cells
or 500 CD56bright NK cells from each donor was included. The
data was clustered based on median fluorescence intensity (MFI)
of the following markers: CD16, CD25, CD44, CD49a, CD56,
CD57, CD69, CD107a, HLA-DR, IFN-γ, KIRs, MIP-1β, NKG2A,
NKG2C, and TNF.
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Staining of Primary Hepatocyte
Primary human hepatocytes were isolated from three organ
donors whose livers were not used for liver transplantation,
acquired from the Karolinska University Hospital, using a
protocol previously described (25). The cells were then stained
fresh with antibodies against MICA, MICB, HLA-ABC, CD155,
ULBP-1, ULBP-2, and ULBP-3 conjugated with PE and analyzed
on a BD FACS Accuri.
Quantification of Soluble MICA and MICB
by ELISA
MICA and MICB solid-phase sandwich ELISAs (enzyme-
linked immunosorbent assay, Thermofisher) were performed
according to the manufacturer instructions. Briefly, human sera
were incubated 2, 5, and 2 h respectively diluted two times
in provided buffers (capture phase). After washing, biotin-
conjugated anti-MICA and MICB antibodies were incubated for
1 h and streptavidin-HRP was added after washing. Unbound
streptavidin-HRP was removed by washing and substrate
solution reactive with HRP was added. The reaction was stopped
by acid after 30min and absorbance measured at 450 nm.
Statistical Analysis
Data were analyzed using Prism Version 6.0 b (GraphPad
Software Inc.; USA). The Mann–Whitney U-test or t-tests were
used depending on if data sets were normally distributed, using
D’Agostino-Pearson omnibus normality test. The threshold for
statistical significance was set to α < 0.05. For analysis of NK
cell population diversity, Simpson Diversity Index (SDI) was
calculated as previously described (26).
RESULTS
Global Assessment of Immune Cells in
NAFL and NASH
To determine the impact of NAFL and NASH on the peripheral
blood immune cell compartment, a broad profiling of major
lymphoid and myeloid immune cells in patients and controls
was initially performed (Figure 1A). Whereas, few differences
were noted among CD4, CD8, and γδ T cells, a trend toward
a decline in MAIT cells was observed in NASH patients as
compared to NAFL patients and healthy controls (Figure 1B). A
decrease of MAIT cells in NASH is in line with recent literature
(27). Regarding NK cells, neither frequency (Figure 1B) nor
absolute numbers (data not shown) were affected by the presence
of obesity, NAFL, or NASH. With respect to the myeloid
immune cell compartment few differences were observed for
monocytes andmyeloidDCs. However, a decline in the frequency
of plasmacytoid DCs (pDCs) was noted in NASH patients
(Figure 1C). Also, the absolute numbers of pDCs were decreased
and the loss of pDCs correlated inversely with the degree
of liver damage measured as serum alanine transferase levels
(Figure 1C). Taken together, although alterations could be
observed in certain innate immune cell subsets, the overall size of
the peripheral blood NK cell compartment remained unaltered in
NAFL and NASH.
Upregulation of NKG2D on NK Cells From
NASH Patients
Since NK cells are far from a homogeneous population, a
more in-depth immune-phenotyping of activating and inhibitory
receptors on circulating NK cells was performed. The CD56dim
to CD56bright NK cell relationship was unaffected in NAFL
and NASH (Figures 2A,B). Next, we simultaneously assessed
expression of 12 surface and intracellular markers on the NK
cells (Figure 2C). As expected, CD56dim NK cells expressed
higher levels of NKG2C, KIRs, and CD57, while CD56bright
NK cells had a higher expression of NKG2A, CD161, CD44,
and NKp46 (Figures 2C,D). Surprisingly, neither the degree of
NAFLD disease severity (Figure 2D) nor presence of obesity
(data not shown) had a detectable effect on the NK cell
receptor repertoire on circulating NK cells, with the exception
for expression of the activating receptor NKG2D. In more detail,
both CD56bright and CD56dim NK cells from patients with NASH
expressed significantly higher levels of NKG2D on their surface
(Figures 2E,F). This was also observed when comparing normal
weight with obese individuals (Figure 2G). However, since NK
cells from NAFL patients had close to normal levels of NKG2D
(Figure 2F), this would suggest that increased expression of
NKG2D primarily associated with NASH. Furthermore, this
increase was specific to NK cells since it was not observed on
T cells from the same patients (data not shown). To dissect
the role of NKG2D more in-depth in relation to the liver and
NAFL we assessed presence of NKG2D-ligands. No difference
in levels of soluble MICA and MICB was noted in patients as
compared to controls (data not shown). Furthermore, primary
human hepatocytes from healthy organ donors were negative for
NKG2D-ligands whereas CD155 and HLA class I was expressed
(Supplementary Figure 1).
Finally, we assessed NK cell differentiation, as determined
by the expression of NKG2A, KIRs, and CD57, as well as NK
cell diversity by calculating Simpson diversity index (SDI) (28,
29). However, both of these metrics for NK cell compartment
composition remained unaltered in NAFL and NASH patients
as compared to healthy controls (Figures 2H,I). In summary,
the phenotype of the circulating NK cell population remains
unaffected by NAFL and NASH with the exception of NKG2D
being upregulated in patients with NASH.
Functional Capacity of Peripheral NK Cell
Subsets in NAFL and NASH
Having determined the NK cell phenotype in peripheral blood,
we next evaluated the functional capacity of NK cells in NAFL
and NASH. To this end, NK cells were stimulated with cytokines
(IL-12+IL-18) and/or K562 target cells and production of IFN-
γ, TNF, MIP-1β, upregulation of CD107a, CD69, CD44, and
CD25, as well as downregulating of CD16 as a consequence of
activation was measured using flow cytometry (Figure 3A). As
expected, stimulation with cytokines led to high levels of IFN-γ
being produced as well as strong upregulation of CD25 and CD69
whereas K562 cell stimulation yielded a robust degranulation
response and elevated levels of TNF and MIP-1β (Figures 3A,B).
When assessing single functional responses, NK cells from
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FIGURE 1 | Immunophenotyping of major peripheral blood immune cell subsets in NAFL and NASH. (A) Flow cytometry gating scheme used to identify the
investigated immune cell subsets. Arrows indicate the sequence of gating. (B) Summary data for the frequency out of total leukocytes for the indicated immune cell
populations in healthy controls (n = 10), NAFL (n = 4), and NASH (n = 11) patients. (C) Summary data of pDC frequency out of total leukocytes (left), absolute
counts of pDCs (middle), and correlation between pDC frequency and ALT (right) in the indicated patient groups. Bars in (B,C) represent mean and error bars show
SEM. **p < 0.01.
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FIGURE 2 | Phenotypic characterization of circulating NK cells from NAFLD patients. (A) Representative flow cytometry plots of NK cells from healthy, NAFL, and
NASH patients. (B) Frequency of CD56bright NK cells out of total NK cells in peripheral blood of healthy controls (n = 13), NAFL patients (n = 9), and NASH patients (n
= 16). (C) Representative histograms for the indicated markers on CD56bright and CD56dim NK cells as well as internal negative control. The plots represent stainings
from one healthy donor. (D) Heat map depicting the mean frequency of NK cells expressing CD16, CD44, CD57, KIRs, NKG2A, and NKG2C as well as the mean MFI
of CD69, NKp46, CD161, Eomes, T-bet, and NKG2D on CD56dim and CD56bright NK cells for the indicated groups. (E) Representative histogram of NKG2D
(Continued)
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FIGURE 2 | expression on NK cells from healthy control, NAFL, and NASH patients respectively. (F,G) Scatter plots of NKG2D MFI on CD56dim and CD56bright NK
cells from the indicated groups. In (F), healthy controls (n = 11), NAFL (n = 6), and NASH (n = 13) patients, in (G) healthy controls (n = 11), obese individuals (n = 18).
(H) Bar graph showing the frequency of CD56dim NK cells that express different combination of NKG2A, KIRs, and CD57. Black circles indicate presence of the
marker and white circles no expression. (I) Inverse Simpson Diversity index (SDI) analysis for healthy (n = 11), NAFL (n = 7), and NASH patients (n = 12). The
Mann–Whitney U-test was used for comparison between groups. Bars in (B,F,G,I) show mean, error bars in H represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
patients with NASH had a similar capacity to degranulate,
produce cytokines, and upregulate activation markers as their
NAFL counterparts and the healthy controls (Figure 3B). Also,
the ability of NK cells to performmultiple functions was retained
in both NAFL and NASH patients as compared to healthy
controls (Figure 3C).
The NK cell compartment consists of many different
subpopulations and NK cells can produce a multitude
of functions in a variegated fashion. Although single or
multifunctional analysis of NK cell functional responses revealed
no considerable alterations in function when comparing NASH
with healthy controls it is plausible that functional difference
might exist in multivariate space not allowing identification
by conventional flow cytometry gating. To address this, we
performed a SNE analysis of the NK cell functional responses
and first generated SNE maps of responding compared to non-
responding NK cells (Figure 3D). These SNE maps segregated
considerably (Figure 3D, residual map) and by projecting the
differences onto the single parameters that formed the basis of the
SNE map the pattern of NK cell responses in multidimensional
space could be revealed (Figure 3D, lower panels). In more detail
this shows how certain NK cell subpopulations responded with
many functions and others only with single function. Together,
this validated the analysis approach and allowed us to compare
patients with healthy controls (Figure 3E and data not shown).
Although the residual plots revealed difference when comparing
responding NK cells from healthy controls with NAFL or NASH
patients (data not shown) or NAFL patients with NASH patients
(Figure 3E), these differences could not be attributed to a
specific phenotype when the residual plot was projected onto the
single parameters (data not shown). This suggests that also in
multi-dimensional space, the NK cell response was unaltered in
NAFL and NASH.
Characterization of NK Cells in Adipose
and Liver Tissue
To this end, characteristics of circulating NK cells have been
analyzed. However, NAFL and NASH are diseases of the liver and
also tightly coupled to obesity, adipose tissue dysregulation, and
reduced insulin sensitivity. Thus, the analysis was focused on NK
cells from liver and adipose tissue. In line with previous literature
(9), NK cells were enriched in the liver compared to peripheral
blood (Figures 4A,B) and a sizeable population of NK cells could
also be detected in visceral adipose tissue. Furthermore, both
types of investigated tissue had a skewing in the distribution of
CD56bright andCD56dim NK cells as compared to circulation with
CD56bright NK cells representing up to half of all NK cells in liver
and adipose tissue (Figure 4B). Also, whereas the differentiation
status of adipose tissue NK cells, with respect to expression of
NKG2A, KIRs, and CD57, mirrored that of circulating NK cells,
differences were observed especially within liver CD56dim NK
cells in expression of these markers (Figures 4C,D).
SNE-analysis of the NK cell compartment identified that
NK cells derived from liver and adipose tissue displayed a
unique phenotype compared to peripheral blood NK cells
(Figure 4E). The major distinction between NK cells derived
from circulation and NK cells derived from tissues was
a higher expression of the tissue residency marker CD69
(Figure 4E). As a consequence of liver and adipose tissue
containing larger populations of CD56bright NK cells, the SNE
analysis also identified higher expression of NKp46, NKG2A,
and CD56 but lower expression of CD16, CD57, and KIRs
within the population enriched in the tissues compared to
in circulation (Figure 4D). This is in line with the overall
phenotypic differences observed when comparing CD56bright
with CD56dim NK cells (Figures 2C,D). Finally, we confirmed
expression of tissue residency markers on liver and adipose
tissue by conventional flow cytometry gating (Figures 4F,G). As
expected, the expression was primarily confined to the CD56bright
NK cells. Interestingly, while CD69 was highly expressed in
both liver and adipose tissue, CD49a was only found on a
small fraction of CD56bright NK cells in the liver whereas
higher expression was noted in adipose tissue (Figures 4F–H).
These results highlight the importance of the organ-specific
microenvironment in shaping the local NK cell population
and emphasize the importance of studying the tissue-resident
compartment when trying to understand the pathogenesis of
diseases affecting peripheral organs.
The Phenotype of Tissue NK Cells Remains
Unaltered in NAFL and NASH
Finally, we assessed the impact of NAFL and NASH disease stage
and severity on the frequency and phenotype of liver and adipose
tissue NK cells (Figure 5). Patients where data on tissue NK
cells were available were stratified based on NAS score (non-
NAFL which represented no steatosis present, NAFL, NASH),
liver fibrosis (fibrosis score 0–1 vs. 2–3), and insulin sensitivity
status (HOMA-IR <4.5 vs. >4.5). Although NK cells were
more abundant in liver (Figure 4B) their frequency remained
unaffected by clinical stage (Figure 5C). Also, the frequency of
NK cells in adipose was unaltered by NAFLD disease activity,
level of fibrosis, and insulin sensitivity (Figure 5C). Finally, the
NK cell phenotype was assessed. Since CD16− and CD16+
NK cells display distinct phenotypes (Figures 2C,D, 4E–G),
these were analyzed separately. For none of the investigated
phenotypic markers, a clear link to the clinical parameters could
be observed (Figure 5D).
Thus, whereas murine models suggest NK cells to play a
distinct role in NAFL andNASH, both the human circulating and
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FIGURE 3 | Retained functional capacity of circulating NK cells in NAFLD. (A) Representative concatenated flow cytometry plots showing CD56dim NK cell responses
following the indicated stimulations. (B) Heat map summarizing the mean frequency of responding NK cells for the measured functions and indicated stimulations in
healthy controls (n = 15), NAFL patients (n = 10), and NASH patients (n = 16). (C) Multifunctional analysis of the combination of degranulation (CD107a) and cytokine
production (IFN-γ, MIP-1β, and TNF) responses for IL-12 + IL-18 stimulation and/or co-culture with K562 target cells. (D) SNE plots of total cells from healthy donors
subsequently divided in stimulated and un-stimulated cells. The residual plot highlights the decreased (blue) or more highly expressed (red) areas in the stimulated
cells. Underneath, individual plots of the expression of 15 single markers are shown. (E) SNE plots depicting the difference between CD56dim (left) and CD56bright
(right) NK cells from NAFL and NASH patients after IL-12 + IL-18 + K562 stimulation where the density plots highlight the specific changes in NASH patients.
peripheral tissue NK cell compartments remain largely intact in
these diseases.
DISCUSSION
NAFLD is the most common chronic liver disease worldwide
and a subgroup of NAFLD patients develop chronic liver
inflammation (NASH) with ensuing fibrosis and increased
risk for HCC. Since little is known regarding NK cells
in this disease and because NK cells are highly enriched
in human liver, we here performed an extensive mapping
of the NK cell compartment in NAFL/NASH using high-
dimensional flow cytometry technology. We assessed the
imprint of liver inflammation in NASH on circulating NK
cells and show specific upregulation of the activating receptor
NKG2D. In addition, by employing bariatric surgery as a
human model, we also comprehensively mapped both liver and
adipose tissue NK cells revealing substantial differences in NK
cell population composition in-between tissues. However, no
significant differences in the tissue-resident NK cell populations
in patients with and without NAFL/NASH were detected.
NK cells have previously been investigated in other chronic
liver diseases, especially in chronic viral hepatitis. These studies
revealed that NK cells have decreased function in chronic
hepatitis C (5, 30, 31). In obese individuals, decreased NK cell
functionality combined with increased activation was reported
(15, 16). A recent study showed that this reduced functionality
was a result of metabolic paralysis of NK cells (18). However,
our study detected no functional defects or changes in activation,
despite both the in-depth and broad evaluation performed.
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FIGURE 4 | Phenotype of NK cells in liver and adipose tissue. (A) Representative flow cytometry plots of NK cells derived from blood, liver, and adipose tissue.
(B) Scatter plot of the frequency of total NK cells out of viable leukocytes and CD16− NK cells out of total NK cells in peripheral blood, liver, and adipose tissue. PBMC
(n = 22), adipose tissue (n = 19), and liver (n = 15). (C) Representative concatenated flow cytometry plots showing expression of differentiation markers NKG2A,
KIRs, and CD57 on CD16− or CD16+ NK cells in blood, liver, and adipose tissue. (D) Bar graphs showing frequency of cells expressing the indicated differentiation
markers in CD16− or CD16+ NK cells from blood, liver, and adipose tissue. PBMC (n = 22), adipose tissue (n = 19), and liver (n = 15). (E) SNE plot of total NK cells
from adipose tissue (left) or liver (right) compared to peripheral blood. The residual plot highlights the decreased (blue) or more highly expressed (red) areas within
tissue NK cells. (F,G) Representative flow cytometry plots showing CD69 and CD49a expression on total NK cells from the indicated tissues. (H) Expression of CD69
and CD49a on CD16− and CD16+ NK cells in peripheral blood, liver, and adipose tissue. In H, CD69 on PBMC (n = 22), adipose tissue (n = 18), and liver (n = 15),
CD49a on PBMC (n = 9), adipose tissue (n = 9), and liver (n = 7). Bars in (B,D,H) represent mean and error bars in (D,H) show SEM. **p < 0.01, ***p < 0.001.
These discrepancies might in part be based on methodological
dissimilarities between the studies, with different target cells
used but also on differing patient inclusion criteria. Indeed,
our patients had, in general, mild fibrosis, with no patients
suffering from cirrhosis, suggesting a more active inflammatory
disease. This compared to other studies where many patients
had cirrhosis (14) or higher BMI (15). Michelet et al identified
functional defects as well as the loss of CD56bright NK cells in
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FIGURE 5 | Tissue NK cells in relation to patient disease characteristics.
(A) Representative hematoxylin and eosin stainings on normal, NAFL, and
NASH liver sections. (B) Distribution of the patients in relation to age, BMI, and
levels of alanine transferase (ALT) as a proxy for liver damage. (C) Heat map
showing mean frequency of total, CD16+, and CD16− NK cells for the
indicated groups. (D) Heat map showing mean frequencies of NKG2A, CD57,
KIRs, NKG2C, CD69, and CD49a expression on CD16− and CD16+ NK cells
for the indicated groups. *p < 0.05.
obese patients (18). This is in line with a previous report (15),
and common of these two studies was that included patients had
BMI’s of up to 50. Our cohort had a considerably lower average
BMI of around 35. Together, this suggests that the functionality of
NK cells and NK cell subset composition is retained in less severe
obesity whereas alterations become evident in patients with
morbid obesity. Atherosclerosis, hypertension, and adipose tissue
inflammation are common comorbidities in NAFLD patients and
thus potential confounding factors that should be controlled for.
Our strategy to address this challenging issue was in one part to
stratify patients into NAFL or NASH by the use of liver biopsies,
considered the gold standard. In addition, we made a subgroup
analysis based on the level of fibrosis and on insulin sensitivity.
However, in none of these comparisons, neither in peripheral
blood nor in liver or adipose tissue, any profound disease-related
alterations in the NK cell populations could be observed. Of note,
we focused our analysis on the major two subpopulations of
NK cells: CD56bright and CD56dim NK cells. Apart from them,
there are additional un-conventional NK cell subset, such as
CD56−CD16+ and CD56dimCD16− NK cells (32), that should
be investigated in future studies.
A recent report demonstrated how chronic hepatitis C
irreversibly causes decreased receptor repertoire diversity in
circulating NK cells (26) Related changes have also been observed
in chronic hepatitis D (33). Based on this, we wanted to
investigate whether the chronic “non-infectious” inflammation
in NAFLD could cause a similarly reduced diversity. However,
NK cell repertoire diversity, determined by SDI, remained intact
in NAFLD. Both NAFLD and chronic viral hepatitis are slowly
developing liver diseases that take years to produce symptoms.
However, manymore changes in serum cytokines can be detected
in hepatitis C patients as compared to NASH patients (34) and it
is plausible that the general degree of inflammation in NASH is
more low-grade as compared to chronic viral hepatitis. Thus, it
might be that a larger inflammatory insult is needed in order to
affect NK cell repertoire diversity.
In experimental models, NK cells have been shown to protect
against liver fibrosis development, e.g., via NKp46-mediated
macrophage activation (13) or by killing of hepatic stellate
cells (HSCs) (35). Similar evidence exists in the human setting
but primarily in relation to chronic viral hepatitis and fibrosis
development (36). NKG2D is another NK cell surface receptor
that may be protective against fibrosis development in mice
by targeting activated HSCs (37). Furthermore, the NKG2D-
ligands MICA andMICB are both upregulated in NASH-livers in
mice (11). For NAFLD patients, level of fibrosis is an important
predictor of long-term survival (38, 39). Interestingly, we could
show that NK cells express higher levels of NKG2D in patients
with NASH. This upregulated NKG2D expression could be a
response to the increased hepatocyte stress, inflammation, and
apoptosis that can be seen in NASH-livers (23). To determine
if NKG2D influenced the degree of liver fibrosis in NAFLD
patients, we compared levels of fibrosis to NKG2D expression on
circulating NK cells but could not detect any association. This
could be due to the fact that fibrosis is a dynamic process that
occurs during many years in NAFLD. In the current study, we
did not have the possibility to investigate NKG2D expression on
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intrahepatic NK cells. Future studies should assess this and also
specifically evaluate the capacity of NK cells to target HSCs (or
hepatocytes) via NKG2D in NAFLD.
Apart from having a protective role in fibrosis development,
adipose tissue NK cells, or ILC1-like cells, have also been shown
to augment insulin resistance in experimental murine models
(19, 20, 40). In more detail, it has been proposed that NK
cells sense stressed cells in adipose tissue, respond with IFN-
γ production, in turn causing macrophage polarization toward
a pro-inflammatory phenotype, which subsequently leads to
insulin resistance (19, 20, 40). However, little is known about
human adipose tissue NK cells in general and also how they relate
to obesity, insulin resistance, and liver disease. In this regard, we
assessed visceral adipose tissue NK cell frequency and phenotype.
Adipose tissue contained a similarly large population of NK
cells as found in peripheral blood. However, adipose tissue was
clearly enriched for CD56brightCD16− NK cells expressing tissue
residency markers. This profile with enrichment of CD56bright
NK cells was similar to the phenotype of NK cells found in
matched liver samples and also to NK cells in many other
peripheral tissues in general (41). Interestingly, the specific subset
of adipose tissue NK cells (or ILC1-like cells) that contribute to
insulin resistance inmice express CD49a on their surface (21, 40).
We here report that also human adipose tissue contains NK cells
expressing CD49a. CD49a+ NK cells had a CD56brightCD16−
phenotype, which is different from liver CD49a+ NK cells (4),
and were more prevalent in adipose tissue as compared to liver
and peripheral blood. However, no link between the presence
and levels of adipose tissue CD49a+ NK cells and the presence of
insulin resistance was noted in the investigated patients. Within
the scope of this study, only CD49a and CD69 was studied
as tissue residency markers. There are a number of additional
surface markers as well as transcription factors that are linked to
tissue residency, which should be investigated in future studies.
Our study design, with liver and adipose tissue biopsies
acquired during laparoscopic surgery, enabled us to uniquely
study NK cells from different peripheral tissues within the
same individual. This analysis revealed interesting features,
emphasizing the different phenotypes of tissue-resident
cells from distinct tissues. We could show that NK cell
differentiation status differed not only between liver and
peripheral blood, in line with previous reports (41), but
also between liver and adipose tissue-derived NK cells. The
pattern of tissue residency marker expression was also distinct
between liver and adipose tissue NK cells within the same
individual. These data emphasize the importance of the
specific local microenvironment in influencing the shape of
the NK cell population. This also shows the importance of,
although cumbersome, studying tissue NK cells in different
human disorders.
Limitations of our study have also to be considered. First,
the target cell line used in the functional experiments consist of
the leukemia cell line K562. While being the gold standard for
assessment of NK cells function, due to its lack of MHC class
I, it is not representative for the NAFLD setting. However, it
does express NKG2D-ligands (42), which primary hepatocytes
derived from organ donors did not (Supplementary Figure 1).
Ideally, future studies should assess NK cell responsiveness
against primary target cells derived from livers of NAFLD
patients, such as hepatic stellate cells or hepatocytes. Second,
in addition to the target cells derived from NASH-livers, future
work should focus on the function of tissue-derived NK cells
since this study, due to practical reasons, only assessed the
function of circulating NK cells. Third, within the scope of
this study, NKG2D expression was only studied on NK cells
derived from peripheral blood. This might not be representative
of NKG2D expression on NK cells derived from liver and
adipose tissue. Fourth, this study does not address the NKG2D-
ligand expression in NASH livers which, in combination with
the NKG2D expression on hepatic NK cells, could provide
interesting insights into the disease mechanisms of NASH.
Thus, the exact role of NKG2D in NAFLD still remains to
be elucidated.
In summary, we here performed a comprehensive assessment
of peripheral blood and tissue NK cells in relation to NAFLD,
the most common chronic liver disease worldwide. Surprisingly,
despite a substantial literature from experimental model systems
suggesting a role for NK cells in NASH, we found a largely
intact NK cell compartment in the human setting. Instead,
our study reveals significant differences in composition of the
NK cell compartment between human peripheral tissues and,
thus, illustrates the importance of understanding the local
microenvironment in shaping the NK cell repertoire.
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